第十一批国家组织药品集采报量启动 允许医疗机构按厂牌报量

Core Viewpoint - The National Organization for Drug Procurement has initiated the 11th batch of centralized drug procurement, allowing medical institutions to report their demand from August 6 to 25, with a focus on optimizing reporting rules and ensuring accurate demand submissions [1][2][3]. Group 1: Procurement Process - The procurement process allows medical institutions to report demand by generic name or specific brand, encouraging participation from recognized companies [1]. - A total of 480 companies submitted relevant drug information, with an average of 15 companies per proposed procurement variety, and some varieties having over 40 companies participating [1]. Group 2: Reporting Requirements - Medical institutions are required to report annual demand for each variety at no less than 80% of the average usage for 2023-2024, with allowances for written explanations in cases of significant demand reduction [1][2]. - The reporting system includes specific annotations for essential drugs and pediatric formulations, allowing institutions to determine conversion ratios if necessary [2]. Group 3: Policy Clarifications - The National Medical Insurance Administration has clarified that while institutions should prioritize selected procurement drugs, they are not restricted to only using these drugs, with 60%-80% of reported demand typically covered by selected drugs [3]. - Historical data indicates that over 80% of medical institutions continue to use selected drugs even after fulfilling their procurement agreements, reflecting a high level of acceptance [3].